Background Cholestatic liver injury is characterised by bile acid accumulation, hepatocyte damage and inflammatory response, leading to fibrosis and potential cirrhosis. Wilms’ tumour-1 associated protein (WTAP), a key regulator of N6-methyladenosine (m6A) modification, plays a crucial role in various diseases. However, the role of WTAP-mediated m6A modification in cholestatic liver diseases has been rarely studied.
Background Cholestatic liver injury is characterised by bile acid accumulation, hepatocyte damage and inflammatory response, leading to fibrosis and potential cirrhosis. Wilms’ tumour-1 associated protein (WTAP), a key regulator of N6-methyladenosine (m6A) modification, plays a crucial role in various diseases. However, the role of WTAP-mediated m6A modification in cholestatic liver diseases has been rarely studied.